Aura Biosciences (AURA) Accumulated Expenses (2020 - 2026)

Aura Biosciences has reported Accumulated Expenses for 7 years, with the latest figure at $10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 55.56% year-over-year to $10.9 million; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (up 55.56% YoY), and the FY2025 full-year result was $6.0 million, up 10.06% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $10.9 million, up from $6.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $13.7 million in Q3 2025, with the low at $2.4 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $6.3 million across 5 years, with a median of $5.5 million in 2024.
• Annual changes were most pronounced in 2024 — Accumulated Expenses plunged 31.42% — and 2025, when it jumped 213.99%.
• Aura Biosciences' Accumulated Expenses stood at $4.6 million in 2022, then soared by 72.38% to $7.9 million in 2023, then sank by 30.79% to $5.5 million in 2024, then advanced by 10.06% to $6.0 million in 2025, then soared by 80.95% to $10.9 million in 2026.
• The last three Accumulated Expenses figures came in at $10.9 million (Q1 2026), $6.0 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.